Alnylam Pharma (ALNY) Misses Q4 EPS by 13c
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $143.71 --0%
Revenue Growth %: +33.0%
Financial Fact:
Net loss: -90.13M
Today's EPS Names:
WF, CWBC, GLTO, More
Revenue Growth %: +33.0%
Financial Fact:
Net loss: -90.13M
Today's EPS Names:
WF, CWBC, GLTO, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q4 EPS of ($1.69), $0.13 worse than the analyst estimate of ($1.56). Revenue for the quarter came in at $258.5 million versus the consensus estimate of $231.44 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alphabet stock surges 11% to record high on Q1 earnings beat, first-ever dividend
- Edwards Lifesciences (EW) Tops Q1 EPS by 2c; offers guidance
- Primis Financial (FRST) Misses Q1 EPS by 8c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
